AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the ...

In the POTOMAC study, one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance ...

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi ...

"The positive results for Imfinzi in the Potomac trial represent a significant advance that will potentially allow more patients with early-stage bladder cancer to benefit from this important ...

Imfinzi plus BCG induction and maintenance therapy showed a statistically and clinically meaningful improvement in DFS for ...

Positive high-level results have been presented by AstraZeneca (LSE: AZN) from the POTOMAC Phase III trial.

Shares of AstraZeneca PLC (AZN) traded 1% higher in pre-market on Friday after the company reported positive results from its ...

Durvalumab plus full BCG significantly improved disease-free survival in high-risk early bladder cancer vs BCG alone in the ...

An evaluation of nearly 19,000 patients with metastatic colorectal cancer supported clinical trial data that immunotherapy ...

Switzerland-based HAYA Therapeutics, a biotech developing precision RNA-guided regulatory genome targeting therapeutics that ...

AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the ...

AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 20,457.50 Crore) operating in Pharmaceuticals sector. AstraZeneca Pharma India Ltd. key ...